Company: CERO
Filing Date: 2025-04-25
Form Type: PRE 14A
Source: 0001213900-25-035562
Chunk: 26

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-25
Form: PRE 14A
Chunk 26
---
103,395 |
| 1-for-75                                        |     |        68,930 |
| 1-for-100                                       |     |        51,698 |
| 1-for-150                                       |     |        34,465 |

____________ (1) Excludes the effect of fractional share treatment. We are exploring various sources of financing, including through potential future sales of Common Stock or other securities. There can be no assurance, however, even if the Reverse Stock Split is approved and implemented, that any financing transaction would be undertaken or completed. If we are unable to successfully raise sufficient additional capital, through future sales of Common Stock or other securities or through strategic and collaborative arrangements, we will not have sufficient cash to fund our planned business operations and or may not be able to continue as a going concern.

11 As of the Record Date, we had 5,169,723shares of Common Stock issued and outstanding, 471,199shares of Common Stock reserved for issuance upon the exercise of outstanding options, 3,405,498shares of Common Stock reserved for issuance upon the exercise of outstanding Warrants (as defined below), and 0shares of Common Stock reserved for future issuances under the 2024 Plan. As of the Record Date, we had 1,429shares of Series A convertible preferred stock, par value $0.0001 per share (the “Series A Preferred Stock”), 198shares of Series B convertible preferred stock, par value $0.0001 per share (the “Series B Preferred Stock”), and 2,537shares of Series C convertible preferred stock, par value $0.0001 per share (the “Series C Preferred Stock”) issued and outstanding. Based upon a conversion price of $1.96, the shares of Series A Preferred Stock are convertible into 729,082shares of Common Stock, the shares of Series B Preferred Stock are currently convertible at the Alternate Conversion Price (as defined below), and based upon a conversion price of $1.96, the shares of Series C Preferred Stock are convertible into 1,294,388shares of Common Stock. If the Alternate Conversion Price is applied to determining the number of shares issuable upon conversion of the outstanding shares of Series A Preferred Stock, Series B Preferred Stock and/or Series C Preferred Stock, the number of shares of Common Stock that would be issuable upon conversion thereof would be based upon 80% of the volume weighted -averageprice (“VWAP”) of the Common Stock during the five trading